The Top Cap 2026 Is Here! Cast Your Vote

Recent Quotes
My Watchlist
Indicators
New Hampshire Stocks
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Invesco Nasdaq Biotechnology ETF (NQ:IBBQ)

36.49 -0.31 (-0.84%)
Streaming Delayed Price Updated: 10:32 AM EDT, Aug 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Invesco Nasdaq Biotechnology ETF

News headline image
Which Biotech ETF Is a Better Buy: Concentrated Bet or Broad Basket? ↗
VanEck's concentrated 25-stock approach offers higher individual company exposure, while Invesco's broader 251-position portfolio delivered 47.4% returns over the past year. 
Via The Motley Fool
Topics ETFs
News headline image
IBBQ vs. PBE: Which Biotech ETF Is the Better Buy? ↗
PBE concentrates on 31 companies and offers a higher dividend yield, while IBBQ spreads risk across 251 holdings at a fraction of the cost. 
Via The Motley Fool
Topics ETFs
News headline image
Invesco Nasdaq Biotech vs. Invesco Pharma: How Do These ETFs Stack Up? ↗
One offers concentrated exposure to 29 pharma giants with lower volatility, while the other provides broader diversification across 251 biotech companies at a cheaper cost. 
Via The Motley Fool
Topics ETFs
uniQure Stock Tumbled 56% Today: What’s The FDA Angle? ↗
Via Stocktwits
News headline image
Which Is the Better Invesco Healthcare ETF: Equal-Weight RSPH or Biotech-Focused IBBQ? ↗
RSPH levels the playing field across 60 established healthcare names while IBBQ bets on more than 250 biotech companies at a lower cost. 
Via The Motley Fool
Topics ETFs
News headline image
XLV vs. IBBQ: Is Broad Healthcare Exposure or Biotech Growth the Better ETF Buy? ↗
IBBQ posted the stronger return over the past year, but has also experienced much higher historical volatility than XLV. 
Via The Motley Fool
Topics ETFs Intellectual Property
News headline image
Better Healthcare Sector ETF: Vanguard's Broad VHT vs. Invesco's Biotechnology-Focused IBBQ ↗
Vanguard's broad sector approach costs half as much and yields twice the dividend, while Invesco's biotech focus delivered stronger 1-year returns but with steeper downside risk. 
Via The Motley Fool
Topics ETFs
News headline image
Is the iShares Healthcare ETF or the Invesco Nasdaq Biotech ETF the Better Bet for Investors in 2026? ↗
One offers global diversification and higher income; the other delivers focused biotech exposure with lower costs and stronger recent gains. 
Via The Motley Fool
Topics ETFs
News headline image
IXJ vs. IBBQ: Global Healthcare vs. Biotech -- Which ETF Is the Better Buy? ↗
IBBQ's concentrated biotech play has delivered a higher one-year return, while IXJ'S diversified global healthcare fund has been much less volatile. 
Via The Motley Fool
Topics ETFs
News headline image
Which is Best for Investors: Healthcare Stability (XLV) or Biotech Growth (IBBQ)? ↗
IBBQ surged 54.5% in one year but carries deeper drawdowns. XLV offers broader diversification, lower costs, and double dividend yield for steadier returns. 
Via The Motley Fool
Topics ETFs
News headline image
Which Healthcare ETF Is the Better Buy: Invesco's IBBQ or State Street's XPH? ↗
IBBQ offers lower costs and broader diversification, while XPH delivered stronger 1-year returns with less volatility. 
Via The Motley Fool
Topics ETFs
News headline image
Biotech ETFs: Which ETF Offers Lower Fees? IBBQ or XPH? ↗
Compare diversification strategies and see how each ETF's unique index focus shapes risk and return for healthcare sector investors. 
Via The Motley Fool
Topics ETFs
News headline image
Alvotech’s Drug Approved In Europe As Biosimilar For Bone Disease Drug ↗
AVT03 will be commercialised in Europe in partnerships with STADA Arzneimittel AG and Dr. Reddy’s, the company said. 
Via Stocktwits
News headline image
Applied Therapeutics To Lay Off Nearly Half Its Staff, Board Explores M&A Options ↗
The board is considering mergers, acquisitions, partnerships, joint ventures, licensing arrangements or other strategic transactions, the company said. 
Via Stocktwits
Topics Workforce
News headline image
Artiva Biotherapeutics Gets A Price Target Hike From Wedbush: Stock Rallies 99% But Retail Expects Further Rally ↗
Wedbush’s new price target implies a whopping 730% potential upside to the stock’s closing price on Thursday. 
Via Stocktwits
News headline image
Mesoblast Gives Positive Update About Potential FDA Application For Heart Failure Therapy: Retail Sees ‘Inflection Point’ ↗
The company is also looking forward to a meeting with the FDA in early July to discuss a trial of Ryoncil in adults with steroid-refractory acute graft-versus-host disease. 
Via Stocktwits
News headline image
These 4 ETFs Provide Smart Exposure To Intuitive Machines, The New Space Economy ↗
Intutive Machines specializes in lunar missions and sophisticated space technologies. These ETFs are worth looking at. 
Via Benzinga
Topics ETFs
News headline image
5 Undervalued ETFs To Ride On Powell's Market Optimism ↗
Here are five ETFs from different zones of the market that are currently undervalued and could generate solid returns in a rising stock market. 
Via Talk Markets
Topics ETFs
News headline image
Tempus AI Stock Eyes Best Rally In 5 Months Amid Pelosi-Linked Hype, But Retail’s Turning Doubtful Now ↗
A regulatory filing from Wednesday night disclosed that Tempus AI founder and CEO Eric Lefkofsky sold 946,084 shares of Tempus between Jan. 15-17. 
Via Stocktwits
Topics Artificial Intelligence
News headline image
FDA Set To Approve COVID-19 Vaccines As Soon As This Week: Stocks, ETFs To Watch ↗
The FDA may approve updated COVID-19 vaccines this week to combat recent strains as the country endures a significant summer outbreak. 
Via Benzinga
Topics ETFs
News headline image
Time For Gilead Sciences-Heavy ETFs? ↗
Gilead Sciences has underperformed the broader market this year by a hefty margin. 
Via Talk Markets
News headline image
Biotech ETFs Pop On M&A Resurgence ↗
The biopharma industry has seen a recent upswing in mergers and acquisitions (M&A). 
Via Talk Markets
News headline image
Is Biotech Immunocore About To Make A 25% Price Move?
Small-cap Immunocore has been a price leader within the biotech industry. Analysts have a "buy" rating on the stock and estimate that it will move 25% higher. 
Via MarketBeat
Topics ETFs
News headline image
Should You Buy Biotech ETFs Now? ↗
Instead of trying to pick winners in this volatile space, it is better to invest in broader biotech ETFs that stand to benefit from increased investor interest and rising spending on drugs and... 
Via Talk Markets
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Gift this article